• 1
    Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 93142.
  • 2
    Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 62932.
  • 3
    Galli M, Barbui T, Zwaal RF, Comfurius P, Bevers EM. Antiphospholipid antibodies: involvement of protein cofactors. Haematologica 1993; 78: 14.
  • 4
    Galli M, Barbui T. Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome. Clin Chem 2001; 47: 9857.
  • 5
    De Laat B, Derksen RH, Urbanus RT, De Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 15405.
  • 6
    Bouma B, De Groot PG, Van Den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, Gros P. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 516674.
  • 7
    Willems GM, Janssen MP, Pelsers MM, Comfurius P, Galli M, Zwaal RF, Bevers EM. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 1383342.
  • 8
    Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, De Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278: 338318.
  • 9
    Lutters BCH, Meijers JCM, Derksen RHWM, Arnout J, De Groot PG. Dimers of β2-glycoprotein I mimic the in vitro effects of β2-glycoprotein I–anti-β2-glycoprotein I antibody complexes. J Biol Chem 2001; 276: 30607.
  • 10
    Riddell DR, Vinogradov DV, Stannard AK, Chadwick N, Owen JS. Identification and characterization of LRP8 (apoER2) in human blood platelets. J Lipid Res 1999; 40: 192530.
  • 11
    Arnout J, Wittevrongel C, Vermylen J. Murine monoclonal antibodies against beta-2-glycoprotein I with lupus anticoagulant activity. Thromb Haemost 1997; 77: 154.
  • 12
    Bu G, Schwartz AL. RAP, a novel type of ER chaperone. Trends Cell Biol 1998; 8: 2726.
  • 13
    Cauwenberghs N, Vanhoorelbeke K, Vauterin S, Westra DF, Romo G, Huizinga EG, Lopez JA, Berndt MC, Harsfalvi J, Deckmyn H. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001; 98: 65260.
  • 14
    Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, De Groot PG, Sixma JJ, Gros P. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 2002; 297: 11769.
  • 15
    Horbach DA, Van Oort E, Donders RCJM, Derksen RHWM, De Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus – comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 91624.
  • 16
    Den Dekker E, Heemskerk JW, Gorter G, Van Der Vuurst H, Donath J, Kroner C, Mikoshiba K, Akkerman JW. Cyclic AMP raises intracellular Ca(2+) in human megakaryocytes independent of protein kinase A. Arterioscler Thromb Vasc Biol 2002; 22: 17986.
  • 17
    Van Lummel M, Pennings MT, Derksen RH, Urbanus RT, Lutters BC, Kaldenhoven N, De Groot PG. The binding site in β2-glycoprotein I for apoER2′ on platelets is located in domain V. J Biol Chem 2005; 280: 3672936.
  • 18
    Weeterings C, Adelmeijer J, Myles T, De Groot PG, Lisman T. Glycoprotein Ibalpha-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flow. Arterioscler Thromb Vasc Biol 2006; 26: 6705.
  • 19
    Remijn JA, Wu YP, IJsseldijk MJ, Zwaginga JJ, Sixma JJ, De Groot PG. Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions. Thromb Haemost 2001; 85: 73642.
  • 20
    Van Os E, Wu YP, Pouwels JG, IJsseldijk MJ, Sixma JJ, Akkerman JW, De Groot PG, Van Willigen G. Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br J Haematol 2003; 121: 48290.
  • 21
    Sakariassen KS, Aarts PAMM, De Groot PhG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 1983; 102: 52235.
  • 22
    De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001; 276: 46928.
  • 23
    Furman MI, Nurden P, Berndt MC, Nurden AT, Benoit SE, Barnard MR, Ofosu FA, Michelson AD. The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. Thromb Haemost 2000; 84: 897903.
  • 24
    Sun B, Li J, Kambayashi J. Interaction between GPIbalpha and FcgammaIIA receptor in human platelets. Biochem Biophys Res Commun 1999; 266: 247.
  • 25
    Arthur JF, Gardiner EE, Matzaris M, Taylor SG, Wijeyewickrema L, Ozaki Y, Kahn ML, Andrews RK, Berndt MC. Glycoprotein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets. Thromb Haemost 2005; 93: 71623.
  • 26
    Padilla A, Moake JL, Bernardo A, Ball C, Wang Y, Arya M, Nolasco L, Turner N, Berndt MC, Anvari B, Lopez JA, Dong JF. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004; 103: 21506.
  • 27
    Shi T, Giannakopoulos B, Yan X, Yu P, Berndt MC, Andrews RK, Rivera J, Iverson GM, Cockerill KA, Linnik MD, Krilis SA. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54: 255867.
  • 28
    Canobbio I, Reineri S, Sinigaglia F, Balduini C, Torti M. A role for p38 MAP kinase in platelet activation by von Willebrand factor. Thromb Haemost 2004; 91: 10210.
  • 29
    Liu JL, Pestina TI, Berndt MC, Jackson CW, Gartner TK. Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alpha IIb beta 3- and aggregation-independent manner. Blood 2005; 106: 27506.
  • 30
    Li ZY, Zhang GY, Feil R, Han JH, Du XP. Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin alpha(IIb)beta(3). Blood 2006; 107: 96572.